COMP <GO>
MOH vs ABBV // 10Y YIELD & FRED MACRO BETA
Molina Healthcare Inc (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: MOH 4
— ABBV 11
▲ 10Y YIELD & FRED MACRO BETA LEADER: ABBV
LAST: $204.78 (+2.93%) • MKT CAP: $10.39B
macro-sensitivity
0.94
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
macro-sensitivity
1.15
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MOH VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MOH | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 13.10% | 70.20% | -57.10 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.20% | 29.00% | -11.80 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 11.4x | 33.3x | -21.90 | MOH | /valuation <GO> |
| Free Cash Flow Yield | -6.12% | 3.47% | -9.59 | ABBV | /fcf-yield <GO> |
| Operating Margin | 1.70% | 24.60% | -22.90 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 1.00% | 6.90% | -5.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 11.70% | 8.60% | +3.10 | MOH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.34 | 5.33 | -0.99 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 7.40% | -0.70 | MOH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.5 | 72.8 | -21.26 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.94 | 1.15 | -0.21 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.5x | 113.1x | -92.60 | MOH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.39B | $513.86B | -$503.47B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MOH REV | ABBV REV | MOH GROSS % | ABBV GROSS % | MOH FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $45.43B | $61.16B | 13.1% | 70.2% | -$636.0M | $17.82B |
| FY 2024 | $40.65B | $56.33B | 15.3% | 70.0% | $544.0M | $17.83B |
| FY 2023 | $34.07B | $54.32B | 44.0% | 44.0% | $128.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MOH // BETA 0.94
ABBV // BETA 1.15